Acute lymphoblastic leukaemia study day
This study day is being organised by Amgen.
Elaine will deliver the morning session, covering:
Part 1:
The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
• A bit about B cells
• Genetic drivers of ALL
• Clonal evolution & intratumoural heterogeneity
• The role of leukaemic stem cells
Treating Philadelphia Chromosome Positive ALL
• Bcr-Abl inhibitors
• Other treatments
Part 2:
Licensed and novel treatments for ALL
• Blinatumumab
• Inotuzumab ozogamicin
• CAR-modified T cells
• Other treatments in trials
Contact Elaine if you would like to know how to book a place.